BrainsWayBRSYF 70 Gross Margin % is 75.17% as of Mar. 2026, which is 2% below its 10-year median of 76.90. GuruFocus rates BRSYF with a GF Score™ of 70/100 and a GF Value™ of $6.71. The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, BrainsWay ranks better than 86.83% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. BrainsWay's Gross Profit for the
three
months ended in Mar. 2026 was $11.68 Mil. BrainsWay's Revenue for the
three
months ended in Mar. 2026 was $15.53 Mil. Therefore, BrainsWay's Gross Margin % for the quarter that ended in Mar. 2026 was 75.17%.
The historical rank and industry rank for BrainsWay's Gross Margin % or its related term are showing as below:
BRSYF'
s Gross Margin % Range Over the Past 10 Years
Min: 73.77 Med: 76.9 Max: 78.94
Current: 75.51
During the past 13 years, the highestGross Margin % of BrainsWay was 78.94%. The lowest was 73.77%. And the median was 76.90%.
BRSYF's Gross Margin % is ranked better than 86.83% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs BRSYF: 75.51
BrainsWay had a gross margin of 75.17% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for BrainsWay was -0.70% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BrainsWay had a gross margin of 75.17% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BrainsWay Gross Margin % Related Terms
BrainsWay Gross Margin % Historical Data
* Premium members only.
The historical data trend for BrainsWay's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, BrainsWay's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrainsWay Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BrainsWay's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BrainsWay (BRSYF) has a Gross Margin % of 75.17% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on BrainsWay and its competitors. This is near median its historical median of 76.90. Over the past decade, BrainsWay's Gross Margin % has ranged from 73.77 to 78.94. According to the industry distribution chart, BrainsWay ranks #106 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 13.2%.
Is BrainsWay's Gross Margin % too high?
BrainsWay's current Gross Margin % of 75.17% is near median its 10-year median of 76.90. Over the past 10 years, this metric has ranged from a low of 73.77 to a high of 78.94. The Medical Devices & Instruments industry median Gross Margin % is 51.94. BrainsWay's value of 75.17% is 44.7% above this industry median. Based on the distribution chart, BrainsWay ranks #106 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BrainsWay has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does BrainsWay's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BrainsWay ranks #106 out of 805 companies for Gross Margin %. This places BrainsWay in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.94. BrainsWay's value of 75.17% is 44.7% above this benchmark. Historically, BrainsWay's own Gross Margin % has ranged from 73.77 to 78.94 over the past decade. While the company's 10-year median is 76.90 vs. the industry median of 51.94, BrainsWay has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrainsWay's current Gross Margin % of 75.17% is 44.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BrainsWay and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrainsWay's current Gross Margin % is 75.17%, which is near median its own 10-year median of 76.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrainsWay stock overvalued right now?
BrainsWay (BRSYF) has a current Gross Margin % of 75.17%. The stock's GF Value™ is $6.71, compared to a current price of $13.55 — trading 101.9% above its estimated fair value. The current Gross Margin % is 75.17%, which is near median its 10-year median of 76.90 and 44.7% above the Medical Devices & Instruments industry median of 51.94. BrainsWay's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BrainsWay (BRSYF), the current Gross Margin % is 75.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrainsWay (BRSYF) Overvalued in 2026?
Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued.
The current stock price of $13.55 is trading 101.9% above its estimated GF Value™ of $6.71.
Key valuation signals for BRSYF:
Gross Margin %: 75.17% (near median its 10-year median of 76.90)
GF Value™: $6.71 vs. price of $13.55 (101.9% above fair value)
Industry Position: 44.7% above the Medical Devices & Instruments median (#106 of 805)
No single metric tells the full story. See the BRSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
70GF Score
Get the complete analysis for BRSYF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRSYF has been successfully added to your 
